Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

348.27 +18.47 (+5.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients ↗
BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regulatory submissions underway and a Phase 3 trial in progress. 
Via Benzinga
News headline image
A Glimpse of BeiGene's Earnings Potential ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
BeiGene's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Affirm Posts Better-Than-Expected Earnings, Joins Ambarella, IREN, Petco Health and Wellness And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
From BeOne Medicines Ltd.
Via Business Wire
News headline image
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up ↗
BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen. 
Via Benzinga
News headline image
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
From BeOne Medicines Ltd.
Via Business Wire
News headline image
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Earnings Scheduled For August 8, 2025 ↗
 
Via Benzinga
News headline image
BeOne Medicines (ONC) Q2 EPS Soars 924% ↗
Via The Motley Fool
News headline image
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Deep Dive Into BeOne Medicines Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
From BeOne Medicines Ltd.
Via Business Wire
News headline image
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About BeOne Medicines ↗
 
Via Benzinga
News headline image
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
From BeOne Medicines Ltd.
Via Business Wire
News headline image
AppLovin, First Solar And Li Auto Are Among Top 10 Large Cap Losers Last Week (June 16-20): Are The Others In Your Portfolio? ↗
Top 10 worst performing large-cap stocks last week: APP, FSLR, JHX, ONC, GSK, ACN, ANET, LI, CPAY, MA. Reasons include short-sell report, tax bill, and market selloff. 
Via Benzinga
News headline image
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
From BeOne Medicines Ltd.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.